Cargando…
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate...
Autores principales: | Shin, Jin Hee, Gadde, Kishore M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626409/ https://www.ncbi.nlm.nih.gov/pubmed/23630428 http://dx.doi.org/10.2147/DMSO.S43403 |
Ejemplares similares
-
Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015) -
Phentermine and topiramate for the management of obesity: a review
por: Cosentino, Gina, et al.
Publicado: (2011) -
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
por: Jordan, Jens, et al.
Publicado: (2014) -
A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
por: Kim, Anthony, et al.
Publicado: (2023) -
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
por: Allison, David B., et al.
Publicado: (2012)